Related Experiment Video
Updated: Jan 8, 2026
Environmental Modulations of the Number of Midbrain Dopamine Neurons in Adult Mice
Published on: January 20, 2015
The RB tumor suppressor: a gatekeeper to hormone independence in prostate cancer?
1Ben May Department for Cancer Research, Gordon Center for Integrative Sciences, University of Chicago, Chicago, Illinois, USA. kmacleod@uchicago.edu
Abstract:
The retinoblastoma tumor suppressor gene (RB1; encoding RB) is often cited as a gatekeeper, whose inactivation - direct or indirect - is a rate-limiting step for tumor initiation. However, in this issue of the JCI, Sharma et al. show that RB1 loss is a late event in human prostate cancer that is coincident with the emergence of castrate-resistant metastatic disease. This role for RB1 was linked to both E2F transcription factor 1-driven upregulation of the androgen receptor (AR) and increased recruitment of the AR to target gene promoters. This unexpected function for RB1 in late-stage cancer calls upon us to reassess the significance of RB1 inactivation in other cancers in terms of its timing, function in disease etiology, and relevance for cancer therapy.
Insights
Loss of the retinoblastoma tumor suppressor gene (RB1) is a late event in prostate cancer, coinciding with castrate-resistant metastasis. RB1 inactivation promotes androgen receptor (AR) activity in advanced disease.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The retinoblastoma tumor suppressor gene (RB1) is traditionally viewed as a gatekeeper, crucial for preventing tumor initiation.
- Its inactivation is often considered a rate-limiting step in early cancer development.
Discussion:
- Sharma et al. demonstrate that RB1 loss occurs late in human prostate cancer progression.
- This loss is associated with the development of castrate-resistant metastatic disease.
Key Insights:
- RB1 loss promotes androgen receptor (AR) signaling by upregulating AR and increasing its promoter recruitment.
- This suggests a novel role for RB1 in late-stage cancer, distinct from its gatekeeper function.
Outlook:
- Re-evaluating the timing and role of RB1 inactivation in various cancers is necessary.
- Understanding RB1's function in late-stage disease may reveal new therapeutic strategies for advanced prostate cancer and other malignancies.
Related Concept Videos
09:21Phenotypic Profiling of Human Stem Cell-Derived Midbrain Dopaminergic Neurons
10:54Reliable Identification of Living Dopaminergic Neurons in Midbrain Cultures Using RNA Sequencing and TH-promoter-driven eGFP Expression
08:45Isolation, Culture and Long-Term Maintenance of Primary Mesencephalic Dopaminergic Neurons From Embryonic Rodent Brains
09:35Environmental Modulations of the Number of Midbrain Dopamine Neurons in Adult Mice
11:58Primary Culture of Mouse Dopaminergic Neurons
09:54Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area